<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), adult <z:mpath ids='MPATH_458'>normal</z:mpath> cytogenetics <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and adult <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro </plain></SENT>
<SENT sid="3" pm="."><plain>MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P&lt;0·05) </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038) </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, MIR29B may be a potential prognostic biomarker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
</text></document>